Allergic diseases and asthma in pregnancy, a secondary publication by Isabella Pali-Schöll et al.
REVIEW Open Access
Allergic diseases and asthma in pregnancy,
a secondary publication
Isabella Pali-Schöll1,3* , Jennifer Namazy2 and Erika Jensen-Jarolim1,3,4
Abstract
Every fifth pregnant woman is affected by allergies, especially rhinitis and asthma. Allergic symptoms existing
before pregnancy may be either attenuated, or equally often promoted through pregnancy. Optimal allergy and
asthma diagnosis and management during pregnancy is vital to ensure the welfare of mother and baby.
For allergy diagnosis in pregnancy, preferentially anamnestic investigation as well as in vitro testing should be
applied, whereas skin testing or provocation tests should be postponed until after birth. Pregnant women with
confirmed allergy should avoid exposure to, or consumption of the offending allergen. Allergen immunotherapy
should not be initiated during pregnancy. In patients on immunotherapy since before pregnancy, maintenance
treatment may be continued, but the allergen dose should not be increased further. Applicable medications for
asthma, rhinitis or skin symptoms in pregnancy are discussed and listed.
In conclusion, i) allergies in pregnancy should preferentially be diagnosed in vitro; ii) AIT may be continued, but not
started, and symptomatic medications must be carefully selected; iii) management of asthma and allergic diseases
is important during pregnancy for welfare of mother and child.
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Background
In the USA, about 18–30% of women in the childbearing
age suffer from allergic diseases, and around 20% of preg-
nant women are affected by allergies, especially rhinitis and
asthma. These two conditions often are present in the same
patient (reviewed in [1, 2]). Other medical conditions that
often complicate pregnancy include allergic conjunctivitis,
acute urticaria, anaphylaxis, food allergy and drug allergy.
Optimal management of these disorders during pregnancy
is vital to ensure the welfare of the mother and the baby
(Fig. 1). In this review, we focus on the current recommen-
dations for diagnosis, management and therapy for allergic
diseases and asthma in women during pregnancy and/or
lactation, as well as on risk factors and preventive measures
for mothers and their children.
Diagnosis of allergy during pregnancy
The diagnosis of allergy in pregnant women should
focus on a detailed medical history and symptom
analysis. For diagnosis, (i) a diary of allergy symptoms
and (ii) avoidance of suspected allergens accompanied
by monitoring of changes of allergic symptoms may be
helpful. It has to be emphasized that it is important not
to put the mother on a rigid elimination diet for
diagnosis of food allergy, as this could negatively influ-
ence the nutritional status of both the mother and the
growing infant.
In vitro diagnostic tools such as serologic tests for
allergen-specific IgE, e.g. ImmunoCAP or radioallergo-
sorbent test (RAST), or the lymphocyte transformation
test for type IV allergy diagnosis are preferred to skin
and provocation tests, which should be postponed until
after birth because of possible, though rare, anaphylactic
reactions [3]. The same applies to food and other chal-
lenge tests. Despite the fact that there are no harmful ef-
fects of patch testing during pregnancy or lactation
known, most physicians deter testing as general precau-
tion, and furthermore because test results can interfere
with immunological changes due to pregnancy [4].
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Management of allergic diseases during pregnancy
Mothers with allergy should avoid exposure to, con-
sumption of and contact with diagnosed specific aller-
gens. Patients should also especially avoid the inhalation
of any potent triggers for asthma, such as animal dander,
house dust, tobacco smoke and irritating pollutants.
Allergen immunotherapy (AIT, SIT, SLIT should
ideally not be initiated during pregnancy because of the
risk of systemic reactions. However, the initiation of im-
munotherapy can be considered in pregnant patients for
clinical high-risk indication like anaphylaxis caused by
Hymenoptera (insect venom) hypersensitivity. For pa-
tients who were already on immunotherapy prior to the
pregnancy, maintenance treatment may be continued
safely during pregnancy [5]. The allergen dose should
not be increased during pregnancy. If pregnancy occurs
while the patient is in the build-up phase of immuno-
therapy and on a low dose, which probably is not thera-
peutic, immunotherapy could also be discontinued [6].
Newer studies indicate that allergen immunotherapy is
not only improving the disease in the pregnant patient,
but that this treatment might also prevent allergic
sensitization in the child. However, more studies are
needed to confirm the effect of allergen immunotherapy
during pregnancy on the development of sensitization in
the child [7].
Medication for asthma and allergy in pregnancy
The ideal situation during pregnancy is “no pharmaco-
logic therapy”, especially during the first trimester. How-
ever, in practice, medications must be considered for
pregnant patients with medical disorders, based on a
thorough appreciation of the potential deleterious effects
of untreated disease in the mother, and also potential
harm for the unborn [8]. For instance, women suffering
from asthma require drug therapy during pregnancy to
prevent life threatening episodes to the mother, as
asthma exacerbations during pregnancy have been linked
to a higher risk of pre-eclampsia, gestational diabetes,
placental abruption and placenta praevia [9]..
Most of the existing data regarding asthma and allergy
medications during pregnancy have not demonstrated
adverse effects (Table 1), even though in infants of
corticosteroid-treated mothers an increased risk of oral
clefts, preeclampsia, preterm birth, and lower birth
weight have been reported. Many of the case controls,
which showed the association between oral corticoster-
oid and oral clefts did not provide information on dose,
duration or indication. Other studies, which have dem-
onstrated association with OCS and preterm delivery
and low birth weight, have been linked with higher doses
for longer periods. For example in Bracken’s study,
which showed an association with OCS use and pre-
eclampsia, the subjects were on OCS for the duration of
pregnancy [10]. However, the potential side effects of
any drug must be balanced against the risks to the
mother or the infant of suffering from inadequately
treated disease.
Treatment of asthma
Certain physiological changes occur normally during
pregnancy, like increased tidal volume and minute
ventilation, and decreased residual volume, functional
residual capacity and diffusion capacity. These alter-
ations are primarily the result of hormonal effects. The
physiologically elevated position of the diaphragm and
hyperventilation occurring in pregnancy further increase
the risk of hypoxia. Preexisting asthma symptoms may
worsen, improve, or remain unchanged during preg-
nancy. Each of these three possibilities is observed in
about one third of cases. Optimal asthma treatment is
crucial [8], as the risk of pre-eclampsia, premature birth,
low birth weight, and maternal and neonatal hypoxia
and morbidity posed by undertreated asthma may be
greater than that from the use of oral steroids for the
treatment of asthma.
Fig. 1 Management of asthma and allergic diseases are
decisive during pregnancy for welfare of mother and child.
(Fotolia.com©Reicher)
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Treatment of acute asthma is similar to that recom-
mended for non-pregnant patients (reviewed in detail in
[11, 12]), including inhaled beta2 agonists, oxygen (es-
sential), and corticosteroids (oral or parenteral). It is also
wise to add nebulized ipratropium bromide in patients
who do not respond to beta2 agonists. Intravenous ami-
nophylline is not generally recommended in the emer-
gency management of acute asthma (because of its
potentially harmful effects) but may be used in pregnant
patients hospitalized for acute asthma (theophylline
levels should be monitored). Intravenous magnesium
sulfate may be beneficial in acute severe asthma as an
adjunct to inhaled beta2 agonists and corticosteroids.
The goals of management of chronic asthma are the
same as those for asthma in general, including preven-
tion of severe exacerbations, improvement of quality of
life (no interference with sleep or daily activities) and
maintenance of normal lung function. The recommen-
dations for medical treatment have been summarized by
the Global Initiative for Asthma (GINA) working group
including management of asthma during pregnancy [15].
A step-wise approach is suggested for medical treatment.
Inhaled salbutamol is the preferred short-acting beta-
agonist, with an outstanding safety profile, and among
inhaled corticosteroids budesonide is preferred based on
the available data. Salmeterol is the preferred agent
when long-acting beta2 agonists are indicated in a preg-
nant woman as add-on treatment for persistent asthma.
Leukotriene modifiers may be used as alternative add-on
treatment: montelukast and zafirlukast are the preferred
anti-leukotriene drugs. Zileuton in contrast, being the
only leukotriene synthesis inhibitor, is not recommended
in pregnancy due to its potential to cause abnormal liver
function (FDA pregnancy category C).
Patients whose asthma is not controlled with maximal
doses of bronchodilators and anti-inflammatory agents
may need systemic corticosteroids. The lowest possible
effective dose should be used. Patients must be moni-
tored closely for potential adverse effects of corticoste-
roids, especially gestational diabetes, preeclampsia, and
Table 1 Recommendations for treatment of asthma and allergies in pregnancy
Drug Safety Data
Common asthma medications and safety data
Inhaled bronchodilators (e.g. Albuterol, Formoterol and Salmeterol) Human data generally reassuring for short acting and long-acting
bronchodilators
Theophylline Reassuring human data; serum levels must be monitored very closely to
avoid toxicity
Systemic corticosteroids Human data from smaller case control studies show increase in oral clefts.
Larger prospective studies show increase in low birth weight, preterm
birth, preeclampsia and intrauterine growth retardation.
Inhaled corticosteroids Human data mainly reassuring. There may be an increased risk of
malformations seen with higher doses.
Leukotriene Receptor Antagonist (e.g. Montelukast, Zafirlukast) Human data are generally reassuring
5-Lipoxygenase-Inhibitor Generally avoided during pregnancy due to the available less reassuring
animal data.
Omalizumab Increased risk of low birth weight and preterm birth; likely severity of
asthma may confound to these observations.
Common allergic rhinitis medications and safety data
Oral antihistamines (e.g. Azelastine, Cetirizine, Chlorpheniramine,
Dexchlorpheniramine, Fexofenadine, Diphenhydramine, Hydroxyzine,
Loratadine)
Human data are generally reassuring.
Hydroxyzine should be used cautiously during first trimester based on
animal data. Fexofenadine (an active metabolite of Terfenedine): no
reports of increased congenital malformations, however, no epidemiologic
studies in human pregnancy available.
Oral and Nasal Decongestants (e.g. Oxymetazoline, Phenylephrine,
Phenylpropanolamine, Pseudoephedrine)
Should be avoided during pregnancy:
Oxymetazoline has been associated with possible uteroplacental
insufficiency at higher doses. Phenylephrine has been associated with
clubfoot and eye/ear malformations. Phenylpropanolamine associated
with congenital malformations, gastroschisis and ventricular septal defect.
Pseudoephedrine associated with gastroschisis, hemifacial microsomia and
small intestinal atresia in some case–control studies.
Intranasal Antihistamines (e.g. Azelastine, Olapatadine) Animal studies are reassuring.
Intranasal Corticosteroids (e.g. Budesonide, Fluticasone, Triamcinolone,
Mometasone)
Substantial reassuring data for inhaled corticosteroids. Risk of increased
malformations at high dose, but severity of allergic rhinitis may be a
confounding factor for these outcomes.
The recommendations from Table 1 have been reviewed in detail in [11, 12] (table modified from [13]). FDA categorization by letters has been removed for
labeling of drugs used during pregnancy and lactation. New FDA regulations for labeling of mediations have been published in 2014 [14]
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intrauterine growth retardation. Based on the available
data, control of maternal asthma is essential to reduce
the risk of perinatal complications. As pregnant women
are hesitant about continuing asthma medications dur-
ing pregnancy, asthma education is a critical component
in the management of the pregnant asthmatic patient.
One of the treatment options for moderate to severe
persistent allergic asthma is the recombinant DNA-
derived humanized IgG1k monoclonal antibody omali-
zumab (Xolair®), which specifically binds to free human
immunoglobulin E (IgE) in the blood. It currently has an
FDA Category B classification based on reassuring ani-
mal studies and the expected limited placental passage
in the first trimester due to the size of the molecule. We
have established an ongoing registry with a target goal of
enrolling 250 asthmatic women treated with omalizu-
mab during pregnancy [16].
Treatment of rhinitis
Significant nasal symptoms occur in approximately 30%
of pregnant women. Pregnancy-associated hormones
have direct and indirect effects on nasal blood flow and
mucous glands. The most common causes of nasal
symptoms necessitating treatment during pregnancy are
allergic rhinitis, rhinitis medicamentosa, sinusitis, and
(non-allergic) vasomotor rhinitis. “Vasomotor rhinitis of
pregnancy” or pregnancy rhinitis is a syndrome of nasal
congestion and vasomotor instability, limited to the ges-
tational period. Allergic rhinitis commonly co-exists
with asthma. As with asthma, pre-existing allergic rhin-
itis can worsen, improve, or remain unchanged during
pregnancy.
The general principles of treatment for pregnant
women with allergic rhinitis [17, 18] –as with asthma-
and do not differ from the step-wise approach recom-
mended for treatment of non-pregnant women. The ini-
tial treatment steps are non-pharmacological and shall
include avoidance of allergens and irritants, furthermore,
nasal lavages with salty water solutions. The mainstays
of pharmacological therapy for allergic rhinitis in non-
pregnant as well as pregnant patients are antihistamines
and intranasal glucocorticoids. No important differences
in efficacy or safety appear to exist between the various
intranasal glucocorticoid preparations. Most pregnant
women who require antihistamines for allergic rhinitis
are appropriately treated with a second generation agent,
because these drugs are less sedating and have fewer
cholinergic side effects compared with first generation
agents. Among second generation antihistamines, lorata-
dine (10 mg once daily) and cetirizine (10 mg once daily)
may be considered the second generation antihistamines
of choice in pregnancy.
For decongestant treatment, there are insufficient
safety data. The narrowing of blood vessel due to this
medication could have negative effects on the fetus, and
furthermore, decongestant nasal sprays can cause addic-
tion. These medications should therefore be avoided
during pregnancy.
Treatment of anaphylaxis
The management of anaphylaxis during pregnancy [3] is
similar to treatment of non-pregnant patients. The first
step is to avoid the trigger of the anaphylactic reaction.
For the treatment of anaphylaxis, epinephrine (adren-
aline) should be promptly injected i.m. Adequate
intravascular volume repletion and oxygenation are par-
ticularly important in the management of anaphylaxis
during pregnancy to prevent both maternal and fetal
complications. The pregnant hypotensive patient should
be placed on her left side to prevent additional
positional hypotension resulting from compression of
the vena cava inferior by the gravid uterus, with her
lower extremities elevated. Intravenous epinephrine may
be required, despite its potential to cause decreased uter-
oplacental blood flow. Glucocorticoids should be admin-
istered early to patients with severe anaphylaxis. For
laryngeal spasm, intubation and in rare cases tracheot-
omy may be necessary.
Treatment of atopic eczema/dermatitis
Gestational itchy dermatoses are relatively common,
with eczema being diagnosed in 36 to 49% of all preg-
nancy dermatoses. Treatment of atopic dermatitis during
pregnancy [19] should emphasize avoidance of triggering
factors and reliance on topical treatment with emollients
to nourish and re-establish the skin barrier. Topical cor-
ticosteroids are prescription-dependent first-line treat-
ment, however, they should only be initiated when
clinically indicated with the least potent effective prepa-
rations. Oral antihistamines (AH) may be required as
systemic treatment. Short-term use of (sedating) first-
generation antihistamines may be beneficial in the set-
ting of sleep loss secondary to itch [20]. Chlorphenir-
amine and diphenhydramine are considered safe during
the first trimester. However, also second-generation
drugs are generally safe, and loratidine is the preferred
second-generation antihistamine in pregnancy (reviewed
in [19]). In general, AH should be used cautiously in the
last month of pregnancy, because of possible withdrawal
symptoms in the child, like poor feeding, diarrhea, irrit-
ability, or tremulousness, which can last up to 4 weeks
after birth [21, 22]. Atopic dermatitis can additionally be
managed with UV phototherapy (UVA, broadband UVA
and UVB, or narrowband UVB).
Treatment of urticaria and angioedema
The pattern and causes of urticaria and angioedema in
pregnancy are similar to those in non-pregnant patients.
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A unique form of urticaria associated with pregnancy
(“pregnancy urticaria”, Pruritic urticarial papules and
plaques of pregnancy PUPPP) mainly occurs in primi-
gravida mothers in the last trimester [23, 24]. The first
step in treatment of urticaria and angioedema [25] in
pregnancy is identification and avoidance of causative
factors. Antihistamines should be avoided if possible, but
if required, the lowest dose of chlorpheniramine, lorata-
dine, or cetirizine may be used.
Risk factors for atopy
The causes of allergy in general and of specific
sensitization in newborns in particular have not been
completely determined yet. Besides the role of genetic
predisposition, some factors have been identified that
may either contribute to sensitization of the mother and
to the subsequent transfer of a predisposition for allergy
to the offspring, or that directly induce sensitization in
the offspring, that manifests shortly after birth or at a
young age (reviewed in [26]).
Family history of atopy/allergy
The degree of risk for atopy/allergy appears to be dir-
ectly related to the family history of allergy and espe-
cially to maternal atopy. If neither parent is allergic, the
chance for allergies in the child is about 5–16%. If one
parent is allergic, the risk increases to 20–40% (father:
33%, mother: 45%), and if both are allergic, the risk is
greater than 40–60% (if patients have the same allergy:
50–80%), especially for developing the same organ-
specific symptoms [27].
Exposure to tobacco smoke
In a recent human study performed by parental ques-
tionnaires, exposure to smoke in utero or during infancy
enhanced the risk for asthma and rhinitis primarily in
early childhood, and the risk for eczema at later ages of
the children [28]. In human blood samples, Th2 cyto-
kines responsible for a predisposition toward allergy
were elevated in the neonates only of mothers who had
smoked during pregnancy. In addition, total and specific
IgE levels, total eosinophil counts, incidence of airway
disease and positive results on skin prick tests were also
increased in children who were exposed to smoke either
during pregnancy or in early childhood [29].
Alcohol consumption
Alcohol consumption by the mother during pregnancy is
associated with higher total IgE levels in cord blood [30]
and furthermore with an increased risk of atopic derma-
titis in the child [31]. Apart from these atopy-associated
negative effects, alcohol consumption should be avoided
during pregnancy due to general health concerns (e.g.
fetal alcohol syndrome).
Maternal diet
Recent research has focused on the role of several essen-
tial nutrients in the diet of the mother, like Vitamin D,
zinc, folate and n-3 polyunsaturated fatty acids (PUFAs)
[32]. Contrasting data exist on the effects of n-3 PUFA.
On the one hand, a diet higher in n-6 polyunsaturated
fatty acids (PUFAs) -as present, for example, in margar-
ine and vegetable oils- seems to be more likely to induce
eczema than n-3 PUFAs, which are found in fish. Ac-
cordingly, several observational studies show that a high
intake of fish and oily fish during pregnancy results in a
reduced incidence of allergy in the children (reviewed in
[33]). On the other hand, a recent Cochrane systematic
review revealed no evidence for supplementation of the
mother with n-3 PUFA during pregnancy and lactation
for prevention of allergy in the child [34].
Current evidence suggests a protective effect of mater-
nal intake of vitamin D, vitamin E, or zinc for wheezing
in childhood, but the data are not conclusive for an ef-
fect on asthma or other atopic conditions [35].
The effect of folate and folic acid supplementation is
intensively discussed. Higher levels in maternal blood
seem to be positively associated with atopic dermatitis in
the offspring [36]. Controversially, recent studies and a
systematic review found no association of prenatal folic
acid supplementation and atopic diseases in children
[37, 38]. Importantly, apart from the effects on atopy
and allergy, sufficient levels of folic acid uptake by the
mother before and during pregnancy have been shown
to reduce the risk for neural tube defects [39].
Regarding allergenic food consumption during preg-
nancy and lactation, there has been extensive reviewing
of data. According to the updated directive (No. 1169/
2011, entered into application on 13 December 2014) of
the Commission of European Communities, the 14 most
allergenic foods have to be labeled on pre-packed food,
and this declaration/information has also to be provided
for non-pre-packed food [40]. These allergen sources are
crustaceans, mollusks, fish, nuts, milk, egg, cereals con-
taining gluten, peanuts, soybeans, sesame, mustard, cel-
ery, lupines, and the products of all these, as well as
sulphur dioxide and sulphites. Some studies suggest that
allergen exposure during pregnancy, lactation and early
childhood may be necessary to induce tolerance [41].
Accordingly, avoidance of allergenic food by the mother,
e.g. milk, egg and nuts during pregnancy, did not appear
to lower the risk of sensitization in the child [42]. More-
over, a balanced diet prevents malnutrition of both
mother and child.
Use of anti-acid medication
Changes of hormone levels during pregnancy and the
growing volume of the fetus often lead to heartburn, re-
flux and abdominal pain in the mother. About 70% of
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pregnant women are affected by these symptoms during
their last trimester and 50% of them are likely to take
acid-suppressing medication. However, animal and hu-
man studies indicate that acid suppression and the
resulting elevated pH in the stomach may lead to an in-
creased risk of sensitization to food ([43, 44], reviewed
in [45]) and drugs [46, 47]. This mechanism was recently
also shown to be true for children aged 0–18 years with
gastro-esophageal reflux disease, who were treated with
gastric acid suppression medication [48]. Importantly, a
sensitization of the mother induced by acid-suppression
was shown to lead to an increased risk of food allergy in
the newborn in a BALB/c mouse model [49]. Also in a
database-link study of human patients, the positive cor-
relation between acid suppression during pregnancy and
increased risk for asthma in children was shown [50].
Although more studies are needed, pregnancy-associated
reflux should probably be treated by non-pharmacological
measures first (avoidance of large meals, sleeping with ele-
vated upper body, not lying down after a meal, avoiding
sweet and fatty food as well as alcohol and smoking). In
general, during pregnancy and lactation, patients should
avoid intake of any medication including non-prescription
over-the-counter substances, unless recommended and
closely monitored by a physician.
Insufficient exposure to environmental bacteria
The “hygiene hypothesis” states that low exposure of the
mother during pregnancy and of the newborn in early
life to environmental bacteria contributes to a Th2-
biased immune response. This hypothesis has been
confirmed by several experimental animal and epidemio-
logical human studies, whereas details about the
mechanism are still under investigation [51].
Cohabitation with pets
In a recent longitudinal study the effects of ownership of
a wide range of pets from pregnancy to 7 years of age
were investigated [52]. Whereas cat ownership was asso-
ciated with lower, rabbit and rodent ownership was asso-
ciated with a higher risk of wheezing. In that study, dog
ownership in pregnancy was associated with wheezing in
the newborn at the age of 6 months. However, in studies
on urban children, especially dog exposure was a clear
protective factor against asthma and allergic diseases, at
least in children without family predisposition for aller-
gies [53]. Dogs also seem to protect from atopic eczema
[54, 55]. The discussion is, however, ongoing. For in-
stance, recent recommendations for the prevention of
food allergy and atopic eczema again contained the rec-
ommendation to avoid pets during gestation [56]. It is
anticipated that an exchange of immunomodulatory al-
lergens such as lipocalins takes place between pets and
humans [57]. Reptiles and exotic pets were so far not
investigated in any birth cohort studies, but potent aller-
gens may be expected from their feeding animals [58].
Conclusion
Diagnosis, preferably by in vitro testing and avoidance of
skin and provocation testing, as well as management of
asthma and allergic diseases are decisive during preg-
nancy for welfare of mother and child. The most import-
ant initial steps for allergic pregnant women are the
avoidance of the offending allergen and the symptomatic
asthma and rhinitis treatment to guarantee optimal oxy-
gen supply, also of the unborn. Allergen-specific im-
munotherapy should not be initiated, but can without
further dose increase be maintained during pregnancy
and lactation.
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